Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Phil on +44 1494 818040 or phil@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Phil Hardy
Senior Account Manager
phil@zenopa.com
+44 1494 818040

Testimonials
I am writing to thank you for your help in finding me a new job. I would like to thank you for your enthusiasm, encouragement and guidance. You certainly helped calm my nerves and boost my confidence.
Alison, 2013

Bayer HealthCare reports positive trial data for Xarelto

25 July 2011 00:00 in Pharmaceutical Company Product News


Bayer HealthCare has reported positive data from a new phase III clinical study of Xarelto, in which the drug met its primary endpoint.

The rivaroxaban therapy has been trialled among Japanese patients in a study called J-Rocket AF, which was conducted among patients with non-valvular atrial fibrillation at risk of stroke, in order to evaluate its safety.

When compared to warfarin, it was shown to offer non-inferior performance when assessing composite criteria of major and non-major clinically relevant bleeding.

Dr Masatsugu Hori, steering committee chairman for the latest trial, said: "It is important that rivaroxaban demonstrated non-inferior safety and that there were numerically fewer intracranial haemorrhages versus warfarin."

Thus far, Xarelto has been approved in more than 85 different countries as a means of preventing venous thromboembolism events among adult patients following elective hip or knee replacement surgery.

Earlier this month, Bayer HealthCare announced a new research alliance with the Ludwig Boltzmann Institute for Lung Vascular Research, which will focus on studies into pulmonary hypertension.ADNFCR-8000103-ID-800632368-ADNFCR

Other news stories from 25/07/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd